GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma
Adding the claudin 18.2 antibody zolbetuximab to CAPOX chemotherapy lengthened survival in claudin 18.2-positive advanced gastric cancer, confirming the SPOTLIGHT result with a different chemotherapy backbone.
Overview
Phase 3 placebo-controlled trial of 507 patients with untreated claudin 18.2-positive (75 percent or more of tumour cells), HER2-negative locally advanced or metastatic gastric or junctional adenocarcinoma randomised to zolbetuximab or placebo with capecitabine and oxaliplatin.
Median progression-free survival was 8.21 versus 6.80 months (hazard ratio 0.687) and median overall survival 14.39 versus 12.16 months (hazard ratio 0.771); nausea and vomiting were the characteristic added toxicities.
- Median overall survival 14.39 vs 12.16 months; hazard ratio 0.771.
- Median progression-free survival 8.21 vs 6.80 months.
Zolbetuximab with either FOLFOX or CAPOX is a first-line standard for claudin 18.2-positive, HER2-negative gastric cancer, making claudin 18.2 testing routine.
- About 38 percent of screened patients were claudin 18.2-positive.
- Nausea and vomiting in the first cycles lead to some discontinuation.
Similar pages
not linked directly; found by shared links- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
- TrialSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- IdeaBiomarker-directed first-line quadruplets in gastric cancer
- TrialSPOTLIGHT & GLOW